Cosmo Reports Phase 2 Study Met Primary Endpoint in Colitis
Cosmo announced topline Phase 2 results for rifamycin 1% topically acting gel in distal ulcerative colitis and ulcerative proctitis.
Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland--(. - October 19, 2026) - Cosmo N.V. SIX:CMHC (FSE: C43) (“Cosmo”) today announced topline results from its Phase 2 study (EUCT number: 2023-506917-23-00) of rifamycin 1% topically acting gel in patients with mildly to moderatel…